Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)

NCT04595747 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04595747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04595747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 3, 2021
Completion date
July 31, 2027
Enrollment
48 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastrointestinal stromal tumor, locally advanced sarcoma, metastatic gastrointestinal stromal tumor, metastatic sarcoma, stage iii gastric and omental gastrointestinal stromal tumor ajcc v8, stage iii small intestinal, esophageal, colorectal, mesenteric, and peritoneal gastrointestinal stromal tumor ajcc v8, stage iv gastric and omental gastrointestinal stromal tumor ajcc v8, stage iv small intestinal, esophageal, colorectal, mesenteric, and peritoneal gastrointestinal stromal tumor ajcc v8